STOCK TITAN
  1. Home
  2. News
  3. TSHA

Taysha Gene Therapies Inc - TSHA STOCK NEWS

Welcome to our dedicated news page for Taysha Gene Therapies (Ticker: TSHA), a resource for investors and traders seeking the latest updates and insights on Taysha Gene Therapies.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Taysha Gene Therapies's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Taysha Gene Therapies's position in the market.

News
Trinity Capital Inc. Provides $40 Million Term Loan to Taysha Gene Therapies
Rhea-AI Summary
Trinity Capital Inc. (NASDAQ: TRIN) commits $40 million in term loans to Taysha Gene Therapies, Inc. (NASDAQ: TSHA) for the clinical development of its lead gene therapy program TSHA-102 in Rett syndrome. Taysha aims to bring novel disease-modifying treatments for CNS diseases with high unmet needs, leveraging AAV-based gene therapies and proven management expertise.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.65%
Tags
none
-
News
Taysha Gene Therapies Announces Expanded Eligibility in REVEAL Phase 1/2 Adult Trial to Include Adolescent Rett Syndrome Patients
Rhea-AI Summary
Taysha Gene Therapies, a clinical-stage gene therapy company (Nasdaq: TSHA), has received authorization from Health Canada for a protocol amendment expanding eligibility to include patients aged 12 and older with stage four Rett syndrome in the REVEAL Phase 1/2 adult trial in Canada. The amendment broadens TSHA-102 treatment potential to both adolescent and adult patients with Rett syndrome. Dosing of the third patient in the adult trial and completion of cohort one are expected in the fourth quarter of 2023/first quarter of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.68%
Tags
clinical trial
-
News
Taysha Gene Therapies Reports Third Quarter 2023 Financial Results and Provides Corporate and Clinical Updates
Rhea-AI Summary
Taysha Gene Therapies, Inc. (Nasdaq: TSHA) reported positive data from the first two adult patients in the REVEAL Phase 1/2 trial for TSHA-102, a gene therapy for Rett syndrome. The results showed sustained improvement across key efficacy measures and new improvement in R-MBA, PGI-I, and hand function. The company also entered into a loan and security agreement with Trinity Capital, extending its cash runway into 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
26.32%
Tags
earnings
News
Taysha Gene Therapies to Release Third Quarter 2023 Financial Results and Host Conference Call and Webcast on November 14
Rhea-AI Summary
Taysha Gene Therapies, Inc. will report Q3 financial results and host a corporate update conference call on November 14, 2023, focusing on AAV-based gene therapies for CNS diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.41%
Tags
earnings
-
News
Taysha Gene Therapies Presents New Preclinical In-vitro Data on TSHA-102 in Rett Syndrome Supporting miRARE Regulation of MECP2 Expression at the European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress
Rhea-AI Summary
Taysha Gene Therapies presents new preclinical data on TSHA-102 in Rett syndrome at ESGCT Congress.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.21%
Tags
none
-
News
Taysha Gene Therapies Announces Two Poster Presentations on TSHA-102 in Rett Syndrome at Upcoming European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress
Rhea-AI Summary
Taysha Gene Therapies to present data on TSHA-102 program for Rett Syndrome at ESGCT Annual Congress
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.97%
Tags
none
News
Taysha Gene Therapies Announces Second Patient Dosed with TSHA-102 in the REVEAL Phase 1/2 Adult Trial for the Treatment of Rett Syndrome
Rhea-AI Summary
Taysha Gene Therapies announces dosing of second Rett syndrome patient with TSHA-102 in adult trial, plans to dose first pediatric patient in 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.01%
Tags
clinical trial
-
News
Taysha Gene Therapies Provides Update on TSHA-120 Program in Giant Axonal Neuropathy (GAN)
Rhea-AI Summary
Taysha discontinues development of TSHA-120 in GAN due to study design challenges, pursues strategic options. Cash runway extended to Q4 2025 for TSHA-102 in Rett syndrome. Astellas declines exclusive license to TSHA-120. FDA recommends randomized trial for TSHA-120 efficacy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.13%
Tags
none
-
News
Taysha Gene Therapies Announces Fast Track Designation Granted by U.S. FDA for TSHA-102 in Rett Syndrome  
Rhea-AI Summary
Taysha Gene Therapies (TSHA) receives Fast Track Designation (FTD) from the FDA for TSHA-102 gene therapy in clinical evaluation for Rett syndrome, highlighting the potential as a meaningful treatment option for patients. Initial data from the first adult patient is encouraging. The company plans to expand the evaluation to pediatric patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.41%
Tags
clinical trial
News
GordonMD® Invests in Private Placement for Taysha Gene Therapies
Rhea-AI Summary
GordonMD Global Investments LP participates in $150 million private placement financing for Taysha Gene Therapies, Inc. to fund clinical development of TSHA-102 in Rett syndrome and program activities for TSHA-120 in giant axonal neuropathy. TSHA-102 receives Orphan Drug and Rare Pediatric Disease designations. Positive development for Taysha Gene Therapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Stock TSHA logo
Taysha Gene Therapies Inc

Nasdaq:TSHA

TSHA Rankings

#3024 Ranked by Market Cap
#681 Ranked by Stock Gains
N/A Ranked by Dividends

TSHA Stock Data

549.83M
100.06M
24.77%
69.83%
9.08%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States
Dallas

About TSHA

taysha gene therapies, inc., a gene therapy company, develops adeno-associated virus based gene therapies for the treatment of monogenic diseases of the central nervous system. it primarily develops tsha-101 for the treatment of gm2 gangliosidosis; tsha-118 for the treatment of cln1 disease; tsha-102 for the treatment of rett syndrome; tsha-103 for the treatment of slc6a1 haploinsufficiency disorder; and tsha-104 for the treatment for surfeit locus 1 deficiency. the company also has strategic partnership with the university of texas southwestern medical center to develop and commercialize transformative gene therapy treatments. taysha gene therapies, inc. was founded in 2019 and is based in dallas, texas.